Black Rock Inc. Leap Therapeutics, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.29 - $0.72 $1,612 - $4,004	5,562 Added 0.91%	619,013 $210,000
Q4 2022 Feb 13, 2023	SELL	$0.42 - $9.18 $237,704 - $5.2 Million	-565,963 Reduced 47.99%	613,451 $276,000
Q3 2022 Nov 14, 2022	SELL	$0.92 - $9.3 $18,051 - $182,475	-19,621 Reduced 1.64%	1,179,414 $1.04 Million
Q2 2022 Aug 12, 2022	BUY	$0.96 - $1.91 $813 - $1,617	847 Added 0.07%	1,199,035 $1.38 Million
Q1 2022 May 12, 2022	BUY	$1.6 - $3.35 $22,526 - $47,164	14,079 Added 1.19%	1,198,188 $2.1 Million
Q4 2021 Feb 10, 2022	BUY	$2.08 - $3.65 $2.06 Million - $3.61 Million	988,647 Added 505.8%	1,184,109 $3.84 Million
Q3 2021 Nov 09, 2021	SELL	$1.35 - $4.01 $19,947 - $59,251	-14,776 Reduced 7.03%	195,462 $784,000
Q2 2021 Aug 11, 2021	BUY	$1.48 - $1.92 $311,152 - $403,656	210,238 New	210,238 $346,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $254M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.